Changing Landscape in the Treatment of Metastatic Renal Cell Carcinoma and Bladder Cancer: Newer Insights

This webcast is co-provided by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet.

For more information visit: www.cancernetus.com

This activity is supported by an independent education grant from Bristol-Myers Squibb.

Scroll to the Bottom of this Information to Begin this Course

Release date: June 30, 2016

Valid through: June 30, 2017

Specialty: Oncology

Topic: Renal Cell Carcinoma and Bladder Cancer

Media: Internet

Estimated Time to Complete Activity: 2.0 hours (120 min)

CME Provider contact information: To contact CME provider, call 214 820 2317

CME Provider Privacy Policy and Contact Information

A. Webb Roberts Center for CME of Baylor Health Care System observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support. To contact CME Provider, call 214-820-2317.

Target Audience

This webcast is designed to meet the educational needs of hematologist/oncologists and other health care professionals who diagnose, treat and manage patients with renal cell carcinoma and bladder cancer.

Statement of Need/Program Overview

This webcast is intended to improve care of patients with renal cell carcinoma and bladder cancer by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the pathogenesis of renal cell carcinoma and bladder cancer the rationale for molecular and immunotherapies
  • Discuss novel immunotherapy with PD-1 and PD-L1 approaches in renal cell carcinoma
  • Assess the emerging role of multitargeted kinase inhibitors in the treatment of renal cell carcinoma
  • Identity the novel immunotherapy approaches with PD-1 and PD-L1 in bladder cancer

Credit Available

  • Physicians — maximum of 2.0 AMA PRA Category 1 Credits™

All other healthcare professionals completing this course will be issued a statement of participation.

Faculty

Daniel Petrylak, MD
Professor of Medicine (Medical Oncology) and of Urology;
Co-Director, Signal Transduction Research Program,
Yale School of Medicine,
New Haven, CT

Brian Rini, MD
Department of Solid Tumor Oncology,
Cleveland Clinic Taussig Cancer Center,
Cleveland, OH

Robert Motzer, MD
Attending Physician,
Memorial Sloan-Kettering Cancer Center,
Professor of Medicine,
Weill Medical College of Cornell University
New York, NY

Jonathan E. Rosenberg, MD
Enno W. Ercklentz Chair,
Genitourinary Oncology Service,
Memorial Sloan Kettering Cancer Center,
New York, NY

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the co-providership of A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet. The A. Webb Roberts Center for CME of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Brian Rini, MD
  • Consultant: Pfizer, Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation
  • Research Support: Pfizer, Bristol-Myers Squibb
Robert Motzer, MD
  • Consultant: Novartis Pharmaceuticals Corporation, Eisai Inc., Pfizer
Daniel Petrylak, MD
  • Consultant: Bayer, Bellicum, Dendreon Corporation, Sanofi US Services, Inc, Johnson and Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche, Tyme Pharmaceuticals
  • Research Support: Oncogenix, Progenics, Johnson and Johnson, Millennium, Celgene, Dendreon Corporation, Sanofi US Services, Inc, Agenysis, Lilly USA, LLC, Roche
  • Stock: Bellicum, Tyme Pharmaceuticals
Jonathan E. Rosenberg, MD
  • Consultant: Agensys, Roche/Genentech, Lilly USA, LLC, Oncogenics, Sanofi US Services, Inc.
  • Stock: Merck, Illumina

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Daniel Petrylak, MD
  • Consultant: Bayer, Bellicum, Dendreon Corporation, Sanofi US Services, Inc, Johnson and Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche, Tyme Pharmaceuticals
  • Research Support: Oncogenix, Progenics, Johnson and Johnson, Millennium, Celgene, Dendreon Corporation, Sanofi US Services, Inc, Agenysis, Lilly USA, LLC, Roche
  • Stock: Bellicum, Tyme Pharmaceuticals
Kamatham A. Naidu, PhD (CancerNet)
  • No relevant financial relationships

All other individuals in a position to control content have no relevant financial relationships to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CME credit for this webcast. During the period June 23, 2016 through June 23, 2017, participants must read all of the material and study the educational webcast.

Instructions for Participation and Credit

This webcast includes text, graphics, and may include multimedia features. There are no fees for participating in or receiving credit for this webcast.

Click on all of the "medical education webcast" links and review the content presented. You must view all of the content to proceed to the post-test.

Read, complete, and submit answers to the post-test questions and evaluation questions online. You must answer all missed questions until you get them correct.

Participants must receive a test score of 100% in order to proceed to the course evaluation, and they must respond to all evaluation questions to receive a letter of credit.

If needed, you may save your answers and return to complete your course at a later date. You can find your saved course by selecting "Your Course History" on the left navigation bar. Then select "View" next to the course you would like to complete.

Letter of Credit & Transcripts

After submitting the webcast evaluation, you may access your letter of credit by selecting "Your Certificates" on the left navigation bar.

Select "Credit" to view letters of credit onscreen and print from your browser. You may print the letter of credit, but you may not alter the letter of credit.

Your credits will be tallied and may be viewed by selecting "View your transcripts" in the "Your Account" area.

Hardware and Software Requirements

Recommends version 6.x browsers or higher from Microsoft or Netscape. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of content. These activities will be marked as such and will provide links to the required software. Required software may include:
Macromedia Flash
Apple QuickTime
Adobe Acrobat
Microsoft PowerPoint
Windows Media Player
RealNetworks RealOne Player
VLC Media Player